Danaher Stock

$190.05

2.43% day before yesterday

NYSE, Jul 18, 10:03 pm CET

ISIN

US2358511028

Symbol

DHR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Danaher Stock price

$190.05

+18.65 10.88% 5Y

NYSE, Closing price Fri, Jul 18 2025

-4.74 2.43%

ISIN

US2358511028

Symbol

DHR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$136.0b

Enterprise Value

$150.5b

Net debt

$14.5b

Cash

$2.0b

Shares outstanding

715.6m

Valuation (TTM | estimate)

P/E

36.4 | 24.4

P/S

5.7 | 5.5

EV/Sales

6.3 | 6.1

EV/FCF

30.7

P/B

2.7

Dividends

DPS

$1.08

Yield 1Y | 5Y

0.6% | 0.4%

Growth 1Y | 5Y

9.2% | 12.4%

Payout 1Y | 3Y

20.4% | 13.9%

Increased

11 Years

Financials (TTM | estimate)

Revenue

$23.8b | $24.7b

EBITDA

$7.5b | $7.7b

EBIT

$5.2b | $6.9b

Net Income

$3.8b | $5.6b

Free Cash Flow

$4.9b

Growth (TTM | estimate)

Revenue

0.4% | 3.6%

EBITDA

4.1% | 2.5%

EBIT

2.6% | 32.5%

Net Income

-14.5% | 42.9%

Free Cash Flow

-11.8%

Financial Health

Equity Ratio

63.9%

Return on Equity

7.9%

ROCE

7.1%

ROIC

5.9%

Debt/Equity

0.3

EPS

$5.2

FCF per Share

$6.9

Short interest

1.2%

Employees

62k

Rev per Employee

$390.0k

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

Danaher Stock Analysis

Unlock Scores for Free

??

31 Analysts have issued a Danaher forecast:

27x Buy

87%

More details on Analyst Estimates Including Price Targets

31 Analysts have issued a Danaher forecast:

Buy

87%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Danaher

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	23,820 23,820	0% 0% 100%
- Direct Costs	9,575 9,575	3% 3% 40%
Gross Profit	14,245 14,245	3% 3% 60%
- Selling and Administrative Expenses	7,489 7,489	3% 3% 31%
- Research and Development Expense	1,595 1,595	6% 6% 7%
EBITDA	7,518 7,518	4% 4% 32%
- Depreciation and Amortization	2,357 2,357	7% 7% 10%
EBIT (Operating Income) EBIT	5,161 5,161	3% 3% 22%
Net Profit	3,765 3,765	14% 14% 16%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Danaher Stock News

Positive

Seeking Alpha

●

2 days ago

45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs

I analyze Barron's Mid-Year 2025 Roundtable Pro Picks using the yield-based 'dogcatcher' method to identify high-yield, safer dividend stocks. AT&T, Tegna, and Pitney Bowes stand out as 'safer' dividend dogs, with prices below annual dividends from $1,000 invested, signaling attractive entry points. The top ten high-yield picks offer projected 24.3% average net gains by July 2026, with lower-th...

Positive

Seeking Alpha

●

20 days ago

Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside

Danaher is positioned for a revenue rebound, led by strong bioprocessing demand and resilient recurring sales, despite short-term headwinds in Life Sciences and China. Margin outlook is stable, supported by a $150M cost-cutting program and proactive tariff mitigation. Shares trade below their 5-year average P/E, offering compelling upside, as growth recovers and margin initiatives take hold.

Neutral

PRNewsWire

●

22 days ago

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

WASHINGTON , June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer.

More Danaher News

Company Profile

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Head office	United States
CEO	Rainer Blair
Employees	62,000
Founded	1984
Website	www.danaher.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now